Roche Pharma Research & Early Development (pRED) Accessing external innovation Michael Schröter – Nov 2012
Transforming deals and external innovation into medicines CHF m
CHF m
Mabthera/Rituxan
6,005 Actemra/RoActemra
618
Avastin
5,292 Xolair
603
Herceptin
5,253 Valcyte/Cymevene
569
Lucentis
1,523 Pulmozyme
492
Pegasys
1,438 Activase/TNKase
453
Xeloda
1,354 Tamiflu
359
Tarceva
1,251 Mircera
344
CellCept
991 Nutropin
317
NeoRec/Epogin
896 Madopar
294
Bonviva/Boniva
696 Neutrogin
278
*2011 sales figures
Partner agreement
In-licensed
2
pRED Strategy – How We Win
Translating science into medical innovation for patients Our focus
Three pillars to execute our strategy
Scientific opportunity and medical need
Our key capabilities to deliver a diverse and high value portfolio
Excel in our Focus Areas Neuroscience Oncology CV & Metabolism Virology
Exploratory Areas 3
Translational Medicine Expertise
Leading Technology Platforms
External R&D Innovation Network
Global Access to Talent Diversity 3
pRED research and translational medicine hubs
A new mode for collaboration with academia
Pharma
Pre-clinical Development
Clinical Development Translational R&D Hub
Partner (universities, institutes, etc.)
Research
• new targets / new molecules • cuttting edge pathway & biology research
Clinic
• selected patient populations • cutting edge technologies (e.g. imaging
Establish, manage and lead a strong networks of academic partnerships to deliver on pRED projects and to enhance the pRED portfolio
4
pRED External Innovation Network
Complementing our capabilities and amplifying our ability to innovate Technology partnerships Harvard • iPSC (stem cells)
PTC Therapeutics
• Advanced treatment options for spinalTechnology muscular atrophypartnerships
Baylor
Translational hubs Singapore
• Network of 26 academic partner institutes, several programs, e.g. angiogenesis • SERI – R&D partnership in Ophthalmology • Virtual R&D unit with financial reimbursements
Netherlands Imaging Hub
• Therapeutic vaccines
• Collaborative Hub of 3 world-class academic imaging sites
Geneva University
French R&D Institute
• Proteomics and pathway analysis
Yissum
• Access to academic innovation network with positive impact on key European affiliate
• Novel pathways, β-cell stem cells discovery, CV risk biomarkers
Montreal Heart Institute
Mt Sinai
Swiss University Network
• Novel screening approaches in Virology
• Cardiovascular center of excellence • Basel, neuroscience cognition research and ETH Zurich, joint Rx / Dx hub
5
Roche Institute for Research & Translational Medicine
A new R&D structure dedicated to partnerships Key features of value for DTAs/ Functions •
48 partnerships with Academic Centers
•
pRED team based in France : Academic Alliance scientists dedicated to local collaborative R&D projects
•
6 Roche Employees + 11 PhD or post-docs
Nanotechnologie s Biomarkers
6
Dutch Imaging Network Allowing pRED to access leading imaging capabilities in Europe Creating a strategic alliance with
Amsterdam
Nijmegen
Key features of value for DTAs/ Functions • World class for imaging antibody distribution •
Excellent clinical and pre-clinical imaging facilities and expertise
•
A novel mode of working together: close scientific collaboration
•
Excellence in imaging for oncology, neuroscience and inflammation
Groningen
Through the Dutch hub we are able to ‘do more, with less’ by leveraging external capabilities rather than utilizing our own expenditure to build up our own capabilities
7
Personalised healthcare as a key enabler
Innovation across the value chain Drug development Research
Early Development
Phase I
Phase II
Launch with Companion Diagnostic
Diagnostic development Discovery & hypothesis generation
Replication
Phase III
Evaluation of biomarkers vs. clinical response
Phase III
Companion Diagnostic Development GLP Biomarker Assay Development 8
We Innovate Healthcare 9
Roche Group – structure
Pharmaceuticals
Diagnostics
10